Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report-Reference-Cited by-同舟云学术

Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report

Published:2022-12-02 Issue:48 Volume:101 Page:e32200
ISSN:1536-5964
Container-title:Medicine
language:en
Short-container-title:

Author:

Kakutani Takuya,Nunokawa Takahiro,Chinen Naofumi,Tamai Yotaro

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference20 articles.

1. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.;Nishimura;Am J Hematol,2021

2. Multicentric Castleman disease: where are we now?;Wang;Semin Diagn Pathol,2016

3. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.;Fajgenbaum;Blood,2014

4. TAFRO syndrome: current perspectives.;Sakashita;J Blood Med,2018

5. Overview of Castleman disease.;Dispenzieri;Blood,2020

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case of TAFRO syndrome after vaccination, successfully treated with cyclosporine;BMC Nephrology;2024-06-13

2. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances;Blood Reviews;2023-12

3. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes;Blood Advances;2023-11-01

4. Case report: Rehabilitation course in thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly syndrome complicated by cerebral infarction in the left parabolic coronary region;Frontiers in Neurology;2023-07-13

5. Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel;HemaSphere;2023-05-23